Browsing Tag
Dilip Shanghvi
2 posts
Sun Pharmaceutical (NSE: SUNPHARMA) bets $11.75bn on Organon (NYSE: OGN) to become a top global pharma player
Sun Pharma is borrowing scale to escape the generics trap. Organon could reshape its global pharma identity if execution holds.
Is Sun Pharmaceutical (NSE: SUNPHARMA) now a wait-for-results stock or an M&A rerating story?
Sun Pharmaceutical (NSE: SUNPHARMA) faces Q4 results, tariff risk, and the Organon bid. Read what could move the stock next.